A Single-dose, Open-label/Pharmacokinetic and Safety Study of SHR4640 in Subjects With Moderate Renal Insufficiency and Healthy Subjects
Latest Information Update: 19 Jul 2024
At a glance
- Drugs Ruzinurad (Primary)
- Indications Hyperuricaemia
- Focus Pharmacokinetics
- Sponsors Jiangsu Hengrui Medicine Co.
Most Recent Events
- 11 Jul 2024 Status changed from recruiting to completed.
- 29 Aug 2023 Status changed from not yet recruiting to recruiting.
- 24 Jul 2023 New trial record